Skip to content

Continuous Ward Monitoring With the GE Portrait Mobile Monitoring Solution: the COSMOS Trial

Continuous Ward Monitoring With the GE Portrait Mobile Monitoring Solution: the COSMOS Trial

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06133140
Acronym
COSMOS
Enrollment
227
Registered
2023-11-15
Start date
2024-02-14
Completion date
2026-01-06
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Complications

Keywords

Postoperative, Anesthesia, Vital signs

Brief summary

The investigators plan to determine whether unblinded continuous ward monitoring with the GE Portrait Mobile Monitoring Solution and nursing alerts reduces vital sign abnormalities in patients recovering from major noncardiac surgery.

Detailed description

Primary Aim. Determine whether unblinded continuous ward monitoring with the GE Portrait Mobile Monitoring Solution and nursing alerts reduces vital sign abnormalities in patients recovering from major noncardiac surgery. Primary hypothesis. Unblinded continuous ward monitoring and nurse alerts reduces vital sign abnormalities during the initial 48 postoperative hours after major non-cardiac surgery while patients remain hospitalized. Secondary Aim. Determine whether continuous ward saturation, ventilation, and pulse rate monitoring reduces a composite of substantive respiratory and cardiovascular interventions. Secondary hypothesis. Unblinded continuous ward monitoring increases a composite of clinical interventions for desaturation, hypoventilation, tachypnea, tachycardia, and bradycardia within 48 hours after major non-cardiac surgery.

Interventions

DEVICEUnblinded postoperative vital sign monitoring

Unblinded postoperative GE Portrait monitoring

DEVICEBlinded postoperative vital sign monitoring

Blinded postoperative GE Portrait monitoring

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Are expected to be admitted to one of the wards equipped with the GE Portrait Mobile Monitoring Solution; 2. Are ≥18 years old; 3. Are designated American Society of Anesthesiologists physical status 1-4; 4. Are scheduled for major noncardiac surgery lasting at least 1.5 hours; 5. Are expected to remain hospitalized at least one postoperative night; 6. Are expected to have general or neuraxial anesthesia.

Exclusion criteria

1. Have language, vision, or hearing impairments that might compromise continuous monitoring; 2. Are designated Do Not Resuscitate, hospice, or receiving end of life care; 3. Are expected to have telemetry monitoring; 4. Have previously participated in the study.

Design outcomes

Primary

MeasureTime frameDescription
Hypoxemia48 postoperative hours.Area of oxygen saturation defined as SpO2 ≤85%.
Inadequate or excessive ventilation48 postoperative hours.Area of inadequate or excessive ventilation defined as respiratory rate ≤4/min or ≥30/min.
Bradycardia and tachycardia48 postoperative hours.Area of inadequate or excessive heart rate defined as ≤40/min or ≥130/min.

Secondary

MeasureTime frameDescription
The fraction of patients who have a composite of interventions potentially related to postoperative vital sign abnormalities.48 postoperative hours.Determine whether continuous ward saturation, ventilation, and pulse rate monitoring reduces substantive respiratory and cardiovascular interventions. Each intervention will be considered dichotomously (occurred or not), and together constitute a composite outcome: * Supplemental oxygen (or substantive dose escalation as indicated by a new administration method) excluding oxygen that patients are already using when they arrive on the ward; * New-onset inhaled drugs (e.g., steroids, bronchodilators); * Naloxone or flumazenil administration; * Non-invasive ventilatory support including bag & mask ventilation, but excluding use of home CPAP and similar devices; * Bolus fluid administration (e.g., \>500 ml); * Drug treatments for bradycardia (e.g., new onset atropine or glycopyrrolate) and discontinuing drugs that promote bradycardia such as beta blockers; * Drug treatment for tachycardia (e.g., new onset beta blockers and calcium channel blockers).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026